Cargando…
Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
BACKGROUND: Trimethylamine N-oxide (TMAO) has been associated with cardiovascular outcomes. However, the diagnostic value of TMAO and its precursors have not been assessed for functionally relevant coronary artery disease (fCAD) and its prognostic potential in this setting needs to be evaluated. MET...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151506/ https://www.ncbi.nlm.nih.gov/pubmed/35220448 http://dx.doi.org/10.1007/s00392-022-01992-6 |
_version_ | 1784717497333710848 |
---|---|
author | Amrein, Melissa Li, Xinmin S. Walter, Joan Wang, Zeneng Zimmermann, Tobias Strebel, Ivo Honegger, Ursina Leu, Kathrin Schäfer, Ibrahim Twerenbold, Raphael Puelacher, Christian Glarner, Noemi Nestelberger, Thomas Koechlin, Luca Ceresa, Benjamin Haaf, Philip Bakula, Adam Zellweger, Michael Hazen, Stanley L. Mueller, Christian |
author_facet | Amrein, Melissa Li, Xinmin S. Walter, Joan Wang, Zeneng Zimmermann, Tobias Strebel, Ivo Honegger, Ursina Leu, Kathrin Schäfer, Ibrahim Twerenbold, Raphael Puelacher, Christian Glarner, Noemi Nestelberger, Thomas Koechlin, Luca Ceresa, Benjamin Haaf, Philip Bakula, Adam Zellweger, Michael Hazen, Stanley L. Mueller, Christian |
author_sort | Amrein, Melissa |
collection | PubMed |
description | BACKGROUND: Trimethylamine N-oxide (TMAO) has been associated with cardiovascular outcomes. However, the diagnostic value of TMAO and its precursors have not been assessed for functionally relevant coronary artery disease (fCAD) and its prognostic potential in this setting needs to be evaluated. METHODS: Among 1726 patients with suspected fCAD serum TMAO, and its precursors betaine, choline and carnitine, were quantified using liquid chromatography tandem mass spectrometry. Diagnosis of fCAD was performed by myocardial perfusion single photon emission tomography (MPI-SPECT) and coronary angiography blinded to marker concentrations. Incident all-cause death, cardiovascular death (CVD) and myocardial infarction (MI) were assessed during 5-years follow-up. RESULTS: Concentrations of TMAO, betaine, choline and carnitine were significantly higher in patients with fCAD versus those without (TMAO 5.33 μM vs 4.66 μM, p < 0.001); however, diagnostic accuracy was low (TMAO area under the receiver operating curve [AUC]: 0.56, 95% CI [0.53–0.59], p < 0.001). In prognostic analyses, TMAO, choline and carnitine above the median were associated with significantly (p < 0.001 for all) higher cumulative events for death and CVD during 5-years follow-up. TMAO remained a significant predictor for death and CVD even in full models adjusted for renal function (HR = 1.58 (1.16, 2.14), p = 0.003; HR = 1.66 [1.07, 2.59], p = 0.025). Prognostic discriminative accuracy for TMAO was good and robust for death and CVD (2-years AUC for CVD 0.73, 95% CI [0.65–0.80]). CONCLUSION: TMAO and its precursors, betaine, choline and carnitine were significantly associated with fCAD, but with limited diagnostic value. TMAO was a strong predictor for incident death and CVD in patients with suspected fCAD. CLINICAL TRIAL REGISTRATION: NCT01838148. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-022-01992-6. |
format | Online Article Text |
id | pubmed-9151506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-91515062022-06-01 Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD) Amrein, Melissa Li, Xinmin S. Walter, Joan Wang, Zeneng Zimmermann, Tobias Strebel, Ivo Honegger, Ursina Leu, Kathrin Schäfer, Ibrahim Twerenbold, Raphael Puelacher, Christian Glarner, Noemi Nestelberger, Thomas Koechlin, Luca Ceresa, Benjamin Haaf, Philip Bakula, Adam Zellweger, Michael Hazen, Stanley L. Mueller, Christian Clin Res Cardiol Original Paper BACKGROUND: Trimethylamine N-oxide (TMAO) has been associated with cardiovascular outcomes. However, the diagnostic value of TMAO and its precursors have not been assessed for functionally relevant coronary artery disease (fCAD) and its prognostic potential in this setting needs to be evaluated. METHODS: Among 1726 patients with suspected fCAD serum TMAO, and its precursors betaine, choline and carnitine, were quantified using liquid chromatography tandem mass spectrometry. Diagnosis of fCAD was performed by myocardial perfusion single photon emission tomography (MPI-SPECT) and coronary angiography blinded to marker concentrations. Incident all-cause death, cardiovascular death (CVD) and myocardial infarction (MI) were assessed during 5-years follow-up. RESULTS: Concentrations of TMAO, betaine, choline and carnitine were significantly higher in patients with fCAD versus those without (TMAO 5.33 μM vs 4.66 μM, p < 0.001); however, diagnostic accuracy was low (TMAO area under the receiver operating curve [AUC]: 0.56, 95% CI [0.53–0.59], p < 0.001). In prognostic analyses, TMAO, choline and carnitine above the median were associated with significantly (p < 0.001 for all) higher cumulative events for death and CVD during 5-years follow-up. TMAO remained a significant predictor for death and CVD even in full models adjusted for renal function (HR = 1.58 (1.16, 2.14), p = 0.003; HR = 1.66 [1.07, 2.59], p = 0.025). Prognostic discriminative accuracy for TMAO was good and robust for death and CVD (2-years AUC for CVD 0.73, 95% CI [0.65–0.80]). CONCLUSION: TMAO and its precursors, betaine, choline and carnitine were significantly associated with fCAD, but with limited diagnostic value. TMAO was a strong predictor for incident death and CVD in patients with suspected fCAD. CLINICAL TRIAL REGISTRATION: NCT01838148. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-022-01992-6. Springer Berlin Heidelberg 2022-02-26 2022 /pmc/articles/PMC9151506/ /pubmed/35220448 http://dx.doi.org/10.1007/s00392-022-01992-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Amrein, Melissa Li, Xinmin S. Walter, Joan Wang, Zeneng Zimmermann, Tobias Strebel, Ivo Honegger, Ursina Leu, Kathrin Schäfer, Ibrahim Twerenbold, Raphael Puelacher, Christian Glarner, Noemi Nestelberger, Thomas Koechlin, Luca Ceresa, Benjamin Haaf, Philip Bakula, Adam Zellweger, Michael Hazen, Stanley L. Mueller, Christian Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD) |
title | Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD) |
title_full | Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD) |
title_fullStr | Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD) |
title_full_unstemmed | Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD) |
title_short | Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD) |
title_sort | gut microbiota-dependent metabolite trimethylamine n-oxide (tmao) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fcad) |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151506/ https://www.ncbi.nlm.nih.gov/pubmed/35220448 http://dx.doi.org/10.1007/s00392-022-01992-6 |
work_keys_str_mv | AT amreinmelissa gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT lixinmins gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT walterjoan gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT wangzeneng gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT zimmermanntobias gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT strebelivo gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT honeggerursina gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT leukathrin gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT schaferibrahim gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT twerenboldraphael gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT puelacherchristian gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT glarnernoemi gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT nestelbergerthomas gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT koechlinluca gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT ceresabenjamin gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT haafphilip gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT bakulaadam gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT zellwegermichael gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT hazenstanleyl gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad AT muellerchristian gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad |